Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth

(2020) Seung-Min Shin et al.   Science Advances

Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges

(2019) Néstor Prieto-Dominguez et al.   Cells

Targeting the untargetable KRAS in cancer therapy

(2019) Pingyu Liu et al.   Acta Pharmaceutica Sinica B

Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?

(2019) Mingtan Tang et al.   JOURNAL OF CONTROLLED RELEASE

Drugging an undruggable pocket on KRAS

(2019) Dirk Kessler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death

(2019) Kyung-A Song et al.   Journal of Thoracic Disease

Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers

(2019) Emily N. Arner et al.   Frontiers in Oncology

EpCAM associates with integrin and regulates cell adhesion in cancer cells

(2019) Jie Yang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Engineering of a tumor cell–specific, cytosol-penetrating antibody with high endosomal escape efficacy

(2018) Ji-sun Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer

(2018) Heather Nesbitt et al.   JOURNAL OF CONTROLLED RELEASE

Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer

(2018) Kiran Tripathi et al.   Journal of Cell Communication and Signaling

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

(2018) Feifei Liu et al.   Acta Pharmaceutica Sinica B

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs

(2018) Joanna Macdonald et al.   Cancers

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer

(2018) Yeo Wool Kang et al.   CANCER LETTERS

Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma

(2018) Xuan Sun et al.   CELLULAR ONCOLOGY

EMT Transition States during Tumor Progression and Metastasis

(2018) Ievgenia Pastushenko et al.   TRENDS IN CELL BIOLOGY

Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes

(2018) Andrew McGuigan et al.   WORLD JOURNAL OF GASTROENTEROLOGY

The roles of ZEB1 in tumorigenic progression and epigenetic modifications

(2018) Yu Zhang et al.   BIOMEDICINE & PHARMACOTHERAPY

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

(2017) Seung-Min Shin et al.   Nature Communications

Targeting Ras with Macromolecules

(2017) Dehua Pei et al.   Cold Spring Harbor Perspectives in Medicine

Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape

(2016) Ji-Sun Kim et al.   JOURNAL OF CONTROLLED RELEASE

Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma

(2016) Neal Bhutiani et al.   JOURNAL OF SURGICAL ONCOLOGY

KRAS-related proteins in pancreatic cancer

(2016) Karen M. Mann et al.   PHARMACOLOGY & THERAPEUTICS

HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer

(2016) Marufa Rumman et al.   Oncotarget

Neoadjuvant therapy for Non-metastatic Pancreatic Ductal Adenocarcinoma

(2015) Megan Winner et al.   SEMINARS IN ONCOLOGY

Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies

(2015) Masami Suzuki et al.   Journal of Toxicologic Pathology

Oncogenic KRAS signalling in pancreatic cancer

(2014) S Eser et al.   BRITISH JOURNAL OF CANCER

The Role of Snail in EMT and Tumorigenesis

(2014) Yifan Wang et al.   CURRENT CANCER DRUG TARGETS

Targeted Drug Delivery Systems for Pancreatic Cancer

(2014) Vaibhav Khare et al.   Journal of Biomedical Nanotechnology

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

KRAS: feeding pancreatic cancer proliferation

(2014) Kirsten L. Bryant et al.   TRENDS IN BIOCHEMICAL SCIENCES

Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals

(2013) K. Miyabayashi et al.   CANCER RESEARCH

Mutant KRAS is a druggable target for pancreatic cancer

(2013) E. Zorde Khvalevsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TWIST1 a New Determinant of Epithelial to Mesenchymal Transition in EGFR Mutated Lung Adenocarcinoma

(2012) Karine Pallier et al.   PLoS One

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

(2012) Chandra Bartholomeusz et al.   Journal of Cancer

Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma

(2010) Zeshaan A. Rasheed et al.   JNCI-Journal of the National Cancer Institute

Interfering with RAS–effector protein interactions prevent RAS-dependent tumour initiation and causes stop–start control of cancer growth

(2010) T Tanaka et al.   ONCOGENE

Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion

(2009) J Chen et al.   BRITISH JOURNAL OF CANCER

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

Targeting AKT with the proapoptotic peptide, TAT-CTMP: A novel strategy for the treatment of human pancreatic adenocarcinoma

(2009) Peter O. Simon et al.   INTERNATIONAL JOURNAL OF CANCER